156 lines
48 KiB
Text
156 lines
48 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-part">
|
|
<meta name="ncbi_acc" content="NBK22981">
|
|
<meta name="ncbi_domain" content="micad">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK22981/?report=reader">
|
|
<meta name="ncbi_pagename" content="Self-quenching Alexa fluor 680 conjugated to trastuzumab - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="chapter">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Self-quenching Alexa fluor 680 conjugated to trastuzumab - Molecular Imaging and Contrast Agent Database (MICAD) - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="auto">
|
|
<meta name="jr-prev-unit" content="/books/n/micad/LLP2A-Alexa680/?report=reader">
|
|
<meta name="jr-next-unit" content="/books/n/micad/sosalexafluor700/?report=reader">
|
|
<meta name="bk-toc-url" content="/books/n/micad/?report=toc">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE">
|
|
<meta name="citation_inbook_title" content="Molecular Imaging and Contrast Agent Database (MICAD) [Internet]">
|
|
<meta name="citation_title" content="Self-quenching Alexa fluor 680 conjugated to trastuzumab">
|
|
<meta name="citation_publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="citation_date" content="2009/04/06">
|
|
<meta name="citation_author" content="Arvind Chopra">
|
|
<meta name="citation_pmid" content="20641189">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK22981/">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Self-quenching Alexa fluor 680 conjugated to trastuzumab">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Center for Biotechnology Information (US)">
|
|
<meta name="DC.Contributor" content="Arvind Chopra">
|
|
<meta name="DC.Date" content="2009/04/06">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK22981/">
|
|
<meta name="description" content="Humanized monoclonal antibodies (MAbs) conjugated to radionuclides used for the detection and treatment of cancers have limited efficacy because they are large glycoprotein molecules (~150 kD) that cannot penetrate deep into cancerous tumors (1). In general, radioimmunoconjugates, including those used for imaging purposes, have a prolonged blood circulation and, if used for radioimmunotherapy ( high-energy β-emitters such as yttrium or rhenium, etc., or α-emitters such as bismuth or astatine, etc.), can impair the functioning of normal cells and may be myelotoxic (1). The use and limitations of radioimmunoconjugates as imaging and therapeutic agents were discussed in detail by Sharkey and Goldenberg (1). As an alternative to using radionuclides in conjunction with MAbs for the detection of cancer, investigators have explored the use of fluorescent agent-MAbs and other molecule conjugates for the preclinical imaging of cancerous tumors (2-6). However, the fluorescent dye-MAb probes, although cheap to generate, have blood circulation and tumor penetration drawbacks similar to the radioimmunoconjugates and also exhibit a high background because of autofluorescence generated in the tissue (6, 7). To circumvent problems observed with the optical probes, investigators have generated self-quenching, targeted fluorescent dye-MAb conjugates that are non-fluorescent in the native state but generate a signal only when activated by degradation of the targeting MAb or molecule by a specific cellular process or organelle (8). Accumulation of the fluorescent dye within a target cell would reduce the non-specific background and decrease the blood pool signal.">
|
|
<meta name="og:title" content="Self-quenching Alexa fluor 680 conjugated to trastuzumab">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:description" content="Humanized monoclonal antibodies (MAbs) conjugated to radionuclides used for the detection and treatment of cancers have limited efficacy because they are large glycoprotein molecules (~150 kD) that cannot penetrate deep into cancerous tumors (1). In general, radioimmunoconjugates, including those used for imaging purposes, have a prolonged blood circulation and, if used for radioimmunotherapy ( high-energy β-emitters such as yttrium or rhenium, etc., or α-emitters such as bismuth or astatine, etc.), can impair the functioning of normal cells and may be myelotoxic (1). The use and limitations of radioimmunoconjugates as imaging and therapeutic agents were discussed in detail by Sharkey and Goldenberg (1). As an alternative to using radionuclides in conjunction with MAbs for the detection of cancer, investigators have explored the use of fluorescent agent-MAbs and other molecule conjugates for the preclinical imaging of cancerous tumors (2-6). However, the fluorescent dye-MAb probes, although cheap to generate, have blood circulation and tumor penetration drawbacks similar to the radioimmunoconjugates and also exhibit a high background because of autofluorescence generated in the tissue (6, 7). To circumvent problems observed with the optical probes, investigators have generated self-quenching, targeted fluorescent dye-MAb conjugates that are non-fluorescent in the native state but generate a signal only when activated by degradation of the targeting MAb or molecule by a specific cellular process or organelle (8). Accumulation of the fluorescent dye within a target cell would reduce the non-specific background and decrease the blood pool signal.">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK22981/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-micad-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/micad/SQAFTra/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK22981/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8E8E857D6418310000000000B700A1.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK22981/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"><div class="head"><a href="/books/n/micad/LLP2A-Alexa680/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="body"><div class="t">Self-quenching Alexa fluor 680 conjugated to trastuzumab</div><div class="j">Molecular Imaging and Contrast Agent Database (MICAD) [Internet]</div></div><div class="tail"><a href="/books/n/micad/sosalexafluor700/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-rtoc-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK22981/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK22981/&text=Self-quenching%20Alexa%20fluor%20680%20conjugated%20to%20trastuzumab"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-rtoc-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Table of Content</div></div><div class="cnt lol f1"><a href="/books/n/micad/?report=reader">Title Information</a><a href="/books/n/micad/toc/?report=reader">Table of Contents Page</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK22981/?report=classic">Switch to classic view</a><a href="/books/NBK22981/pdf/Bookshelf_NBK22981.pdf">PDF (143K)</a><a href="/books/NBK22981/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK22981%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8E8E857D6418310000000000B700A1.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><div class="fm-sec"><h1 id="_NBK22981_"><span class="title" itemprop="name">Self-quenching Alexa fluor 680 conjugated to trastuzumab</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Tra-Alexa680(SQ)</div><p class="contribs">Chopra A.</p><p class="fm-aai"><a href="#_NBK22981_pubdet_">Publication Details</a></p></div></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figSQAFTraT1"><a href="/books/NBK22981/table/SQAFTra.T1/?report=objectonly" target="object" title="Table" class="img_link icnblk_img" rid-ob="figobSQAFTraT1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="SQAFTra.T1"><a href="/books/NBK22981/table/SQAFTra.T1/?report=objectonly" target="object" rid-ob="figobSQAFTraT1">Table</a></h4><p class="float-caption no_bottom_margin">
|
|
|
|
<i>In vitro</i>
|
|
|
|
|
|
Rodents
|
|
</p></div></div><div id="SQAFTra.Background"><h2 id="_SQAFTra_Background_">Background</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=alexa+680+conjugated+to+trastuzumab" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Humanized monoclonal antibodies (MAbs) conjugated to radionuclides used for the detection and treatment of cancers have limited efficacy because they are large glycoprotein molecules (~150 kD) that cannot penetrate deep into cancerous tumors (<a class="bibr" href="#SQAFTra.REF.1" rid="SQAFTra.REF.1">1</a>). In general, radioimmunoconjugates, including those used for imaging purposes, have a prolonged blood circulation and, if used for radioimmunotherapy ( high-energy β-emitters such as yttrium or rhenium, etc., or α-emitters such as bismuth or astatine, etc.), can impair the functioning of normal cells and may be myelotoxic (<a class="bibr" href="#SQAFTra.REF.1" rid="SQAFTra.REF.1">1</a>). The use and limitations of radioimmunoconjugates as imaging and therapeutic agents were discussed in detail by Sharkey and Goldenberg (<a class="bibr" href="#SQAFTra.REF.1" rid="SQAFTra.REF.1">1</a>). As an alternative to using radionuclides in conjunction with MAbs for the detection of cancer, investigators have explored the use of fluorescent agent-MAbs and other molecule conjugates for the preclinical imaging of cancerous tumors (<a class="bibr" href="#SQAFTra.REF.2" rid="SQAFTra.REF.2 SQAFTra.REF.3 SQAFTra.REF.4 SQAFTra.REF.5 SQAFTra.REF.6">2-6</a>). However, the fluorescent dye-MAb probes, although cheap to generate, have blood circulation and tumor penetration drawbacks similar to the radioimmunoconjugates and also exhibit a high background because of autofluorescence generated in the tissue (<a class="bibr" href="#SQAFTra.REF.6" rid="SQAFTra.REF.6 SQAFTra.REF.7">6, 7</a>). To circumvent problems observed with the optical probes, investigators have generated self-quenching, targeted fluorescent dye-MAb conjugates that are non-fluorescent in the native state but generate a signal only when activated by degradation of the targeting MAb or molecule by a specific cellular process or organelle (<a class="bibr" href="#SQAFTra.REF.8" rid="SQAFTra.REF.8">8</a>). Accumulation of the fluorescent dye within a target cell would reduce the non-specific background and decrease the blood pool signal.</p><p>The chemical structure of self-quenching probes is such that a quencher molecule is closely associated in alignment with the fluorophore. Enzymatic cleavage of the structure results in separation of the quencher from the fluorophore and in the generation of a fluorescent signal (<a class="bibr" href="#SQAFTra.REF.8" rid="SQAFTra.REF.8">8</a>). Near-infrared (NIR) probes such as Alexa fluor and Cy5.5 are favored over other optical agents because they exhibit superior tissue penetration (hemoglobin and water have low absorption of the NIR signal at the operating wavelengths of these probes), and when two or more NIR probe molecules are conjugated, the fluorescent signal quenches itself. Cleavage of the conjugation bonds results in fluorescence dequenching and generation of a signal that is suitable for imaging (<a class="bibr" href="#SQAFTra.REF.9" rid="SQAFTra.REF.9 SQAFTra.REF.10 SQAFTra.REF.11">9-11</a>). However, it is pertinent to mention that only a specific number of the NIR probe molecules can be conjugated to a macromolecule without changing the structural and pharmacokinetic properties of the macromolecule. Ogawa et al. conjugated multiple copies of Alexa fluor 680 (Alexa680) to trastuzumab (Tra), a humanized MAb that specifically targets the human epidermal growth factor receptor 2 (HER2), to synthesize a self-quenching, targeted NIR probe (Tra-Alexa680(SQ)) (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>). Tra is <a href="http://www.herceptin.com/index.jsp?s_cid=0001&s_src=googleppc&segmentID=1530&gclid=CPmJ952fj5kCFQu-Ggod1FuMbQ" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">approved</a> by the United States Food and Drug Administration for use as a single agent or an adjuvant to treat certain types of breast cancer and is being tested in <a href="http://clinicaltrials.gov/ct2/results?term=trastuzumab" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">clinical trials</a> for the treatment of other neoplasms in humans. A characteristic feature of HER2 is that, upon binding a ligand, including the MAb directed against it, the receptor-ligand complex is internalized by the cell for enzymatic digestion in the lysosomes (<a class="bibr" href="#SQAFTra.REF.13" rid="SQAFTra.REF.13 SQAFTra.REF.14">13, 14</a>). Proteolytic digestion of the receptor and the bound MAb in the lysosome releases the quencher from the fluorophore, resulting in generation of a signal. Therefore, a fluorophore that is “off” in the extracellular environment is turned “on” in an intracellular location. Ogawa et al. investigated the receptor specificity of Tra-Alexa680(SQ) under <i>in vitro</i> conditions using NIH-3T3 cells transfected with the HER2 gene (3T3/HER2<sup>+</sup> cells), and to study the <i>in vivo</i> characteristics of the fluorophore-MAb conjugate the investigators used nude mice bearing xenograft and orthotropic tumors generated with 3T3/HER2<sup>+</sup> or BALB/3T3/HER2<sup>-</sup> cells (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>).</p></div><div id="SQAFTra.Synthesis"><h2 id="_SQAFTra_Synthesis_">Synthesis</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%22SUBSTANCENAME%22%5BSubstance%20Name%5D%20AND%20synthesis" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Synthesis of the self-quenching Tra-Alexa680(SQ) conjugate was detailed by Ogawa et al. (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>). Alexa680 (as a N-hydroxysuccinimide ester) and Tra were obtained from commercial sources. Briefly, the Tra-Alexa680(SQ) conjugate was synthesized by incubating Tra with Alexa680 in phosphate buffer (pH 8.5) for 30 min at room temperature. The conjugate was purified on a Sephadex G50 column and stored at 4°C as a stock solution. Approximately seven Alexa680 molecules conjugated to each MAb molecule, as determined with absorption on a UV-Vis spectrophotometric system.</p><p>A control “always on” conjugate, Tra-Alexa680(ON), was also synthesized, purified, and stored as above. The Tra-Alexa680(ON) conjugate was reported to have approximately one Alexa680 molecule per Tra molecule, as determined above (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>).</p><p>The yield, purity, and stability of either conjugate, after purification, was not reported.</p></div><div id="SQAFTra.In_Vitro_Studies_Tes"><h2 id="_SQAFTra_In_Vitro_Studies_Tes_"><i>In Vitro</i> Studies: Testing in Cells and Tissues</h2><p>[<a href="/entrez/query.fcgi?cmd=PureSearch&db=pubmed&details_term=%22SUBSTANCENAME%22%5BSubstance%20Name%5D%20AND%20in%20vitro" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>Ogawa et al. used a fluorescence spectrometer to investigate the fluorescence quenching ability of the Tra-Alexa680 conjugates by exposing them to 5% sodium dodecyl sulfate and 1% 2-mercaptoethanol in phosphate-buffered saline for 2 min at 95°C (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>). The quenching capacities of Tra-Alexa680(SQ) and Tra-Alexa680(ON) were reported to be 8- and 2-fold, respectively compared to the native (undenatured),self quenching, molecules (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>).</p><p>The <i>in vitro</i> binding specificity of the Tra-Alexa680 conjugates was studied with the use of 3T3/HER2<sup>+</sup> and the control BALB/3T3(HER2<sup>-</sup>) cells as described by Ogawa et al. (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>). The two cell types were exposed to Tra-Alexa680 conjugates and viewed under a fluorescent microscope after 1 and 8 h. At 1 h, cell surface fluorescence was observed only on the 3T3/HER2<sup>+</sup> cells, and at 8 h the fluorescence was emitted by fluorescent dots located inside the cells. A higher fluorescent signal was reported for cells treated with Tra-Alexa680(SQ) than for those treated with Tra-Alexa680(ON). A fluorescent signal due to Tra-Alexa680(ON) binding or internalization was not observed with the BALB/3T3/ZsGreen/HER2<sup>-</sup> cells (these cells were transfected with the green fluorescent protein gene) when exposed respectively to either conjugate. This indicated that the two Tra-Alexa680 conjugates were bound to, and internalized by, only the HER2<sup>+</sup> cells.</p></div><div id="SQAFTra.Animal_Studies"><h2 id="_SQAFTra_Animal_Studies_">Animal Studies</h2><div id="SQAFTra.Rodents"><h3>Rodents</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=alexa+680+conjugated+to+trastuzumab+rodentia" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p><i>In vivo</i> and <i>ex vivo</i> imaging studies performed with nude mice bearing 3T3/HER2<sup>+</sup> and BALB/3T3/ZsGreen/HER2<sup>-</sup> cell tumors were described by Ogawa et al. (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>). The mice were injected with either Tra-Alexa680(SQ) or Tra-Alexa680(ON), respectively (number of animals used per conjugate was not reported), and imaging was performed 2 d after administration of the conjugates. Whole-body imaging of the animals revealed that the 3T3/HER2<sup>+</sup> tumor images were much more enhanced compared to those generated with the BALB/3T3/ZsGreen/HER2<sup>-</sup> cells. Also, with Tra-Alexa680(ON), the fluorescent signal was obtained not only from the HER2<sup>+</sup> cells but also from the HER2<sup>-</sup> cells, although the signal generated from the latter cells was considerably lower. <i>Ex vivo</i> imaging of the tumors yielded results similar to those obtained during the whole-body imaging studies (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>). In addition, the fluorescent signal obtained from the blood pool was reported to be low with Tra-Alexa680(SQ) compared with Tra-Alexa680(ON). Similar results were also reported with animals bearing 3T3/HER2<sup>+</sup> and BALB/3T3/ZsGreen/HER2<sup>-</sup> cell orthotropic tumors (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>).</p><p>With results obtained from this study, the investigators concluded that it is possible to apply this technology to other humanized MAbs of the immunoglobulin G<sub>1</sub> class for the development of targeted imaging agents (<a class="bibr" href="#SQAFTra.REF.12" rid="SQAFTra.REF.12">12</a>).</p></div><div id="SQAFTra.Other_NonPrimate_Mam"><h3>Other Non-Primate Mammals</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=alexa+680+conjugated+to+trastuzumab+Non+Primate+Mammals" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div><div id="SQAFTra.NonHuman_Primates"><h3>Non-Human Primates</h3><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=alexa+680+conjugated+to+trastuzumab+Non+Human+Primates" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div></div><div id="SQAFTra.Human_Studies"><h2 id="_SQAFTra_Human_Studies_">Human Studies</h2><p>[<a href="/sites/entrez?Db=pubmed&Cmd=DetailsSearch&Term=alexa+680+conjugated+to+trastuzumab+Human+Studies" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">PubMed</a>]</p><p>No references are currently available.</p></div><div id="SQAFTra.Supplemental_Informa"><h2 id="_SQAFTra_Supplemental_Informa_">Supplemental Information</h2><p>[<a href="/books/n/micad/disclaimer/?report=reader">Disclaimers</a>]</p></div><div id="SQAFTra.NIH_Support"><h2 id="_SQAFTra_NIH_Support_">NIH Support</h2><p>Some studies in this chapter were supported by grants from the National Institutes of Health Intramural Research Program, the National Cancer Institute, and the Center for Cancer Research.</p></div><div id="SQAFTra.References"><h2 id="_SQAFTra_References_">References</h2><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="SQAFTra.REF.1">Sharkey R.M., Goldenberg D.M.
|
|
<em>Novel radioimmunopharmaceuticals for cancer imaging and therapy.</em>
|
|
<span><span class="ref-journal">Curr Opin Investig Drugs. </span>2008;<span class="ref-vol">9</span>(12):1302–16.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19037837" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19037837</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="SQAFTra.REF.2">Amoh Y., Katsuoka K., Hoffman R.M.
|
|
<em>Color-coded fluorescent protein imaging of angiogenesis: the AngioMouse models.</em>
|
|
<span><span class="ref-journal">Curr Pharm Des. </span>2008;<span class="ref-vol">14</span>(36):3810–9.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/19128234" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19128234</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="SQAFTra.REF.3">Barrett T., Koyama Y., Hama Y., Ravizzini G., Shin I.S., Jang B.S., Paik C.H., Urano Y., Choyke P.L., Kobayashi H.
|
|
<em>In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies.</em>
|
|
<span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">13</span>(22 Pt 1):6639–48.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17982120" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17982120</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="SQAFTra.REF.4">Koyama Y., Hama Y., Urano Y., Nguyen D.M., Choyke P.L., Kobayashi H.
|
|
<em>Spectral fluorescence molecular imaging of lung metastases targeting HER2/neu.</em>
|
|
<span><span class="ref-journal">Clin Cancer Res. </span>2007;<span class="ref-vol">13</span>(10):2936–45.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17504994" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17504994</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="SQAFTra.REF.5">Sampath L., Wang W., Sevick-Muraca E.M.
|
|
<em>Near infrared fluorescent optical imaging for nodal staging.</em>
|
|
<span><span class="ref-journal">J Biomed Opt. </span>2008;<span class="ref-vol">13</span>(4):041312.</span> [<a href="/pmc/articles/PMC2914597/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2914597</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19021320" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19021320</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="SQAFTra.REF.6">Pierce M.C., Javier D.J., Richards-Kortum R.
|
|
<em>Optical contrast agents and imaging systems for detection and diagnosis of cancer.</em>
|
|
<span><span class="ref-journal">Int J Cancer. </span>2008;<span class="ref-vol">123</span>(9):1979–90.</span> [<a href="/pmc/articles/PMC2902964/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2902964</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18712733" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18712733</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>7.</dt><dd><div class="bk_ref" id="SQAFTra.REF.7">Cai W., Chen X.
|
|
<em>Multimodality imaging of vascular endothelial growth factor and vascular endothelial growth factor receptor expression.</em>
|
|
<span><span class="ref-journal">Front Biosci. </span>2007;<span class="ref-vol">12</span>:4267–79.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/17485373" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 17485373</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>8.</dt><dd><div class="bk_ref" id="SQAFTra.REF.8">Lee S., Park K., Kim K., Choi K., Kwon I.C.
|
|
<em>Activatable imaging probes with amplified fluorescent signals.</em>
|
|
<span><span class="ref-journal">Chem Commun (Camb). </span>2008;(36):4250–60.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18802536" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18802536</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>9.</dt><dd><div class="bk_ref" id="SQAFTra.REF.9">Bremer C., Ntziachristos V., Weissleder R.
|
|
<em>Optical-based molecular imaging: contrast agents and potential medical applications.</em>
|
|
<span><span class="ref-journal">Eur Radiol. </span>2003;<span class="ref-vol">13</span>(2):231–43.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12598985" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12598985</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>10.</dt><dd><div class="bk_ref" id="SQAFTra.REF.10">Ntziachristos V., Bremer C., Weissleder R.
|
|
<em>Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging.</em>
|
|
<span><span class="ref-journal">Eur Radiol. </span>2003;<span class="ref-vol">13</span>(1):195–208.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12541130" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12541130</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>11.</dt><dd><div class="bk_ref" id="SQAFTra.REF.11">Wunderbaldinger P., Turetschek K., Bremer C.
|
|
<em>Near-infrared fluorescence imaging of lymph nodes using a new enzyme sensing activatable macromolecular optical probe.</em>
|
|
<span><span class="ref-journal">Eur Radiol. </span>2003;<span class="ref-vol">13</span>(9):2206–11.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/12802615" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12802615</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>12.</dt><dd><div class="bk_ref" id="SQAFTra.REF.12">Ogawa M., Regino C.A., Choyke P.L., Kobayashi H.
|
|
<em>In vivo target-specific activatable near-infrared optical labeling of humanized monoclonal antibodies.</em>
|
|
<span><span class="ref-journal">Mol Cancer Ther. </span>2009;<span class="ref-vol">8</span>(1):232–9.</span> [<a href="/pmc/articles/PMC2790275/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2790275</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19139133" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19139133</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>13.</dt><dd><div class="bk_ref" id="SQAFTra.REF.13">Ogawa M., Kosaka N., Choyke P.L., Kobayashi H.
|
|
<em>In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green.</em>
|
|
<span><span class="ref-journal">Cancer Res. </span>2009;<span class="ref-vol">69</span>(4):1268–72.</span> [<a href="/pmc/articles/PMC2788996/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2788996</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19176373" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 19176373</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>14.</dt><dd><div class="bk_ref" id="SQAFTra.REF.14">Palyi-Krekk Z., Barok M., Kovacs T., Saya H., Nagano O., Szollosi J., Nagy P.
|
|
<em>EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.</em>
|
|
<span><span class="ref-journal">Cancer Lett. </span>2008;<span class="ref-vol">263</span>(2):231–42.</span> [<a href="https://pubmed.ncbi.nlm.nih.gov/18276068" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 18276068</span></a>]</div></dd></dl></dl></div><div id="bk_toc_contnr"></div></div></div><div class="fm-sec"><h2 id="_NBK22981_pubdet_">Publication Details</h2><h3>Author Information and Affiliations</h3><div class="contrib half_rhythm"><span itemprop="author">Arvind Chopra</span>, PhD<div class="affiliation small">National Center for Biotechnology Information, NLM, NIH, Bethesda, MD 20894<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="vog.hin.mln.ibcn@dacim" class="oemail">vog.hin.mln.ibcn@dacim</a></div></div></div><h3>Publication History</h3><p class="small">Created: <span itemprop="datePublished">March 5, 2009</span>; Last Update: <span itemprop="dateModified">April 6, 2009</span>.</p><h3>Copyright</h3><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div></div><h3>Publisher</h3><p><a href="http://www.ncbi.nlm.nih.gov/" ref="pagearea=page-banner&targetsite=external&targetcat=link&targettype=publisher">National Center for Biotechnology Information (US)</a>, Bethesda (MD)</p><h3>NLM Citation</h3><p>Chopra A. Self-quenching Alexa fluor 680 conjugated to trastuzumab. 2009 Mar 5 [Updated 2009 Apr 6]. In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013. <span class="bk_cite_avail"></span></p></div><div class="small-screen-prev"><a href="/books/n/micad/LLP2A-Alexa680/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a></div><div class="small-screen-next"><a href="/books/n/micad/sosalexafluor700/?report=reader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div></article><article data-type="table-wrap" id="figobSQAFTraT1"><div id="SQAFTra.T1" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK22981/table/SQAFTra.T1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__SQAFTra.T1_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Chemical name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Self-quenching Alexa fluor 680 conjugated to trastuzumab</td><td rowspan="9" colspan="1" style="text-align:left;vertical-align:middle;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Abbreviated name:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Tra-Alexa680(SQ)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Synonym:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Agent Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Humanized monoclonal antibody</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Epidermal growth factor receptor 2 (HER2)</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Target Category:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Receptor</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Method of detection:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Optical imaging: fluorescence</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Source of signal / contrast:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Alexa fluor 680</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Activation:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Yes</td></tr><tr><td rowspan="1" colspan="1" style="text-align:right;vertical-align:top;">
|
|
<b>Studies:</b>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" />
|
|
<i>In vitro</i>
|
|
|
|
</div></li></ul>
|
|
<ul class="simple-list"><li class="half_rhythm"><div>
|
|
<img alt="Checkbox" src="/corehtml/pmc/css/bookshelf/2.26/img/studies.checkbox.png" /> Rodents
|
|
</div></li></ul>
|
|
</td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Click here for information regarding <a href="/sites/entrez?Db=gene&Cmd=retrieve&dopt=full_report&list_uids=1956&log$=databasead&logdbfrom=protein" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">human EGFR</a>.</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal107 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|